Arrowhead Appoints Patrick O’Brien as General Counsel
December 04 2014 - 3:53PM
Business Wire
Arrowhead Research Corporation (NASDAQ: ARWR), a
biopharmaceutical company developing targeted RNAi therapeutics,
today announced that it has appointed Patrick O’Brien as General
Counsel. In this role, Mr. O’Brien will have overall responsibility
to manage all of the Company’s legal matters.
“Patrick will be an integral part of the Arrowhead management
team,” said Christopher Anzalone, Ph.D., Arrowhead’s President and
Chief Executive Officer. “His twenty year history of representing
and advising biopharmaceutical companies from multiple vantage
points will be a great asset as we move forward.”
Mr. O’Brien comes to Arrowhead from Shire where he served as
Group Vice President, Legal in Shire’s Boston office. Prior to
that, he was Chief Legal Officer for Shire’s regenerative medicine
division. Mr. O’Brien has also served as Assistant General Counsel
for Johnson & Johnson and Vice President, Law of its Centocor
Ortho-Biotech business unit, Regulatory Counsel at the U.S. Food
and Drug Administration, and as outside counsel to
biopharmaceutical high technology companies while engaged in
private practice. He holds B.S. in Pharmacy, Pharm.D., and J.D.
degrees from the University of Arizona.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company
developing targeted RNAi therapeutics. The company is leveraging
its proprietary Dynamic Polyconjugate delivery platform to develop
targeted drugs based on the RNA interference mechanism that
efficiently silences disease-causing genes. Arrowhead’s pipeline
includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver
disease associated with Alpha-1 antitrypsin deficiency, and
partner-based programs in obesity and oncology.
For more information please visit
http://www.arrowheadresearch.com, or follow us on Twitter
@ArrowRes. To be added to the Company's email list and receive news
directly, please visit
http://ir.arrowheadresearch.com/alerts.cfm.
NASDAQ Notice
As an inducement to entering into employment with the Company,
on December 2, 2014, new employees of the Company were awarded an
"inducement" grant of options and restricted stock units (RSU)
under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option
entitles the new employees to purchase, outside of the Company's
stockholder approved equity incentive plans, an aggregate of up to
120,000 shares of the Company's common stock at an exercise price
per share of $5.22, the last reported closing price of the
Company's common stock on the date of grant and 30,000 restricted
stock units. The option vests and becomes exercisable over a period
of four years from the date of grant and the RSUs vest annually in
three equal installments.
Source: Arrowhead Research Corporation
Arrowhead Research CorporationVince Anzalone,
CFA626-304-3400ir@arrowres.comorInvestor Relations:The Trout
GroupLauren Glaser646-378-2972ir@arrowres.comorMedia:Russo
PartnersMartina Schwarzkopf,
Ph.D.212-845-4292martina.schwarzkopf@russopartnersllc.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2024 to May 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From May 2023 to May 2024